https://www.selleckchem.com/pr....oducts/VX-680(MK-045
In the JAVELIN Lung 200 trial, avelumab (anti-programmed death-ligand 1 [PD-L1] antibody) did not significantly prolong overall survival (OS) versus docetaxel in patients with platinum-treated PD-L1+ NSCLC. We report greater than 2-year follow-up data. Patients with stage IIIB or IV or recurrent NSCLC with disease progression after platinum-doublet chemotherapy were randomized 11 to avelumab 10 mg/kg every 2 weeks or docetaxel 75 mg/m every 3 weeks. The primary end point was OS in patients with PD-L1+ tumors (greater than or equ
Like
Comment
Share
